Growth Hormone Benefits: What Studies Report

The phrase growth hormone benefits covers a very wide range of expectations, but the published literature is not evenly spread across them. Most of the controlled trial evidence sits in paediatric endocrinology, where growth hormone is an approved replacement therapy and the measured outcome is height velocity. Outside that setting the literature thins quickly, and in some domains people ask about there are no trials in the verified evidence set at all. This page organises what studies actually measured, in whom, and in which direction the results pointed. It does not recommend anything. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, symptom or treatment decision. A broader background overview is available in the growth hormone learn page.

Outcome domains at a glance

The table below maps each outcome domain to the type of study that examined it and the direction researchers reported. Every row links the source in the same cell.

Linear growth in children with growth hormone deficiency

This is the domain with randomized, controlled, head-to-head data. The phase 3 study of weekly somatrogon compared it with daily somatropin in children with growth hormone deficiency and reported non-inferiority on annual height velocity at 12 months (PMID 35405011). The randomized phase 3 REAL4 trial evaluated weekly somapacitan in children with growth hormone deficiency and reported that the weekly regimen was effective and well tolerated in that population (PMID 36062966).

Two points are worth separating. First, the comparator in both trials was daily growth hormone, not placebo — the research question was whether a less frequent injection schedule matched an established therapy, not whether growth hormone increases growth in deficiency, which was already the basis for approval. Second, the population was children with a diagnosed deficiency. Nothing in either trial speaks to adults with normal growth hormone production (PMID 35405011, PMID 36062966).

Pooled and review-level evidence on long-acting formulations

A systematic review and meta-analysis compared long-acting growth hormone replacement with daily growth hormone in children with growth hormone deficiency across efficacy, safety, quality of life, adherence and cost-effectiveness — a wider set of endpoints than height alone (PMID 37236413). Two narrative reviews map the same field: one summarising the state of long-acting growth hormone as of 2022 (PMID 36967745) and a 2025 clinics review of long-acting growth hormone preparations and their clinical handling (PMID 41130656). Reviews of this kind organise existing trials; they do not generate new effect estimates, and that distinction matters when a review is cited as if it were evidence of a benefit (PMID 36967745).

Idiopathic short stature: a different question

Idiopathic short stature describes children who are short without an identified growth hormone deficiency or other diagnosis. A 2025 paper in Growth Hormone & IGF Research set out to examine the efficacy, safety and outcomes of growth hormone treatment in children with idiopathic short stature (PMID 40848513). Readers comparing this literature with the deficiency trials should note that the starting physiology differs: in deficiency, treatment replaces a missing hormone, whereas in idiopathic short stature it is given to children whose own axis tests as intact, which is why efficacy and safety are examined as separate questions in that work (PMID 40848513).

Reproductive medicine and endometrial receptivity

Growth hormone has been studied as an adjuvant in assisted reproduction. A 2019 review in Frontiers in Endocrinology addressed growth hormone and endometrial receptivity, drawing together mechanistic reasoning and the clinical literature in that area (PMID 31616379). Because it was a review rather than a trial, it contributed no new randomized outcome data, and the evidence it describes should not be read as a demonstration that growth hormone improves pregnancy outcomes (PMID 31616379).

Aging, body composition and the "anti-aging" framing

The most directly relevant document in this evidence set is the 2023 Endocrine Society scientific statement on hormones and aging, which reviewed how endocrine axes — including the growth hormone/IGF-1 axis — change across the lifespan and how that evidence bears on hormone treatment in older adults (PMID 37326526). A scientific statement is an expert synthesis, and it is the appropriate document to consult precisely because the aging field is dominated by small studies and strong marketing claims rather than large outcome trials (PMID 37326526).

What the verified literature here does not contain is any randomized trial of growth hormone in healthy adults for muscle gain, fat loss, skin quality, energy, libido, sleep depth, longevity or athletic performance. Those outcomes are frequently attached to growth hormone in popular writing. In this citation set they are unmeasured, and an absence of trials is not a weak positive result — it is no result at all, which is why the aging statement frames the question at the level of axis physiology rather than outcome promises (PMID 37326526).

Delivery engineering: pulsatility and patches

Endogenous growth hormone is secreted in pulses, and some research targets the delivery pattern rather than the molecule. A 2025 report in Nature Materials described a biorhythm-mimicking growth hormone patch, work that sits at the materials and device-development stage rather than at the stage of clinical efficacy trials in patients (PMID 40181125). Preclinical delivery research of this type establishes feasibility of a release profile; it does not establish clinical benefit, and the gap between the two is typically years of additional study (PMID 40181125).

The counterweight: what excess growth hormone does

Any discussion framed around benefits is incomplete without the literature on growth hormone excess. A clinical review of growth hormone excess set out its implications and management, describing the multisystem consequences that follow sustained oversupply of the hormone (PMID 36237164). A separate review described pegvisomant, a growth hormone receptor antagonist, in the treatment of acromegaly — that is, a drug whose therapeutic purpose is to block growth hormone signalling (PMID 36402555). Taken together, these two reviews show that the dose–response relationship for growth hormone is not one-directional: more signalling is a disease state with its own treatment pathway, not an enhanced version of health (PMID 36237164, PMID 36402555).

A nearby literature that is often confused with this one

Searches about growth hormone frequently surface work on the growth hormone secretagogue receptor (GHSR), the ghrelin receptor. A randomized, double-blind, placebo-controlled study tested a GHSR blocker in people with alcohol use disorder (PMID 39704175). The direction is the opposite of growth hormone administration — the intervention blocked a receptor in the broader growth hormone axis — and the outcome domain was addiction medicine, not growth or body composition, so the trial does not support any claim about growth hormone benefits (PMID 39704175).

Tolerability and Adverse Events: What Studies Report

Safety was a co-primary concern in the paediatric trials rather than an afterthought. The phase 3 somatrogon study reported on safety alongside efficacy in children with growth hormone deficiency (PMID 35405011), and the REAL4 trial characterised weekly somapacitan as well tolerated in the same population (PMID 36062966). At the pooled level, the systematic review and meta-analysis of long-acting versus daily growth hormone included safety among its prespecified comparison domains (PMID 37236413), and the 2025 review of long-acting preparations discusses how these products are handled clinically (PMID 41130656). Safety reported in a monitored paediatric deficiency trial does not transfer to unmonitored use in other populations, and the growth hormone excess review describes what sustained oversupply looks like clinically (PMID 36237164).

How to read this evidence base

• Match the population. Trial results in children with diagnosed deficiency were generated in that group only (PMID 36062966).
• Check the comparator. Non-inferiority against daily growth hormone answers a scheduling question, not a benefit-versus-nothing question (PMID 35405011).
• Separate reviews from trials. Narrative reviews organise the field; they do not add outcome data (PMID 36967745).
• Label preclinical work. Device and materials research reports feasibility, not clinical outcomes (PMID 40181125).
• Read the harm literature too. Growth hormone excess has its own management pathway (PMID 36402555).

In short, researchers have built a solid, repeatedly replicated evidence base for one indication and a much thinner one everywhere else, with the aging question addressed at the level of a scientific statement rather than outcome trials (PMID 37326526). Anyone weighing claims found elsewhere can ask three questions of each: who was studied, what was measured, and what was the comparison.

References

• Hormones and Aging: An Endocrine Society Scientific Statement (The Journal of Clinical Endocrinology and Metabolism, 2023)
• Biorhythm-mimicking growth hormone patch (Nature Materials, 2025)
• Growth Hormone and Endometrial Receptivity (Frontiers in Endocrinology, 2019)
• Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study (The Journal of Clinical Endocrinology and Metabolism, 2022)
• Long-acting growth hormone in 2022 (Pediatric Investigation, 2023)
• Long-acting Growth Hormone Preparations (Endocrinology and Metabolism Clinics of North America, 2025)
• Efficacy, safety, and outcomes of growth hormone treatment in children with idiopathic short stature (Growth Hormone & IGF Research, 2025)
• Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial (The Journal of Clinical Endocrinology and Metabolism, 2022)
• [Pegvisomant in the treatment of acromegaly] (Vnitrni Lekarstvi, 2022)
• Growth Hormone Excess: Implications and Management (Endocrine, Metabolic & Immune Disorders Drug Targets, 2023)
• Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis (Pharmacological Research, 2023)
• A randomized, double-blind, placebo-controlled study of a GHSR blocker in people with alcohol use disorder (JCI Insight, 2024)